ASMB实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...

Stats
今日成交量	4 556.00
平均成交量	24 204.00
市值	72.10M
EPS	$0 ( 2024-05-02 )
下一个收益日期	( $-3.23 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.980
ATR14	$0.0400 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	White Nicole S	Buy	3 333	Common Stock
2024-04-30	White Nicole S	Sell	1 255	Common Stock
2024-04-29	Okazaki Jason A	Buy	4 166	Common Stock
2024-04-30	Okazaki Jason A	Sell	1 569	Common Stock
2024-04-29	Delaney William E Iv	Buy	3 333	Common Stock

INSIDER POWER
65.30
Last 96 transactions
Buy: 3 858 062 \| Sell: 644 587

Assembly Biosciences Inc 相关性

10 最正相关
TARS	0.932
FLXS	0.929
BUFF	0.925
EYEG	0.925
KBWP	0.925
LDHA	0.924
LVRA	0.922
DXJS	0.921
MSDAU	0.921
LFAC	0.921

10 最负相关
MYMD	-0.924
TBLT	-0.922
LLNW	-0.921
AGRX	-0.919
IRDM	-0.918
CFRX	-0.916
MSEX	-0.915
AGFY	-0.914
SINT	-0.914
GP	-0.912

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Assembly Biosciences Inc 财务报表

Annual	2023
营收:	$7.16M
毛利润:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2023
营收:	$7.16M
毛利润:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2022
营收:	$0
毛利润:	$-498 000 (0.00 %)
EPS:	$-22.82

FY	2021
营收:	$6.25M
毛利润:	$0.00 (0.00 %)
EPS:	$-3.67

Financial Reports:

No articles found.

Assembly Biosciences Inc

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.